In a report released yesterday, Joseph Schwartz from Leerink Partners maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), ...

Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for PTC Therapeutics in a report ...

William Blair increased their FY2024 earnings estimates for PTC Therapeutics in a report issued on Monday, January 13th.

Leerink Partners analyst Joseph Schwartz has maintained their neutral stance on PTCT stock, giving a Hold rating yesterday.Stay Ahead of the ...

PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet its primary and secondary efficacy endpoints.The biotech company said ...

PTC Therapeutics stock launched north of a profit-taking zone Monday after Novartis agreed to pay up to $2.9 billion to license its Huntington's treatment. Please watch the video at Investors.com ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common ...

More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up ...

WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing ...